EU Accelerated Approval Nod For Daiichi Sankyo/AZ’s Enhertu
Daiichi-Sankyo has received a CHMP positive opinion for use of the antibody-drug conjugate in HER2-positive breast cancer, making this the third major market for the product.
You may also be interested in...
Major Japanese firm sets targets under a new mid-term plan that envisages the US oncology sector leading growth and revenues, and also casts an eye to novel assets beyond three pillar antibody-drug conjugates and new digital technologies.
Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.